



Attorney Docket No.: 3745.234-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Efendic et al

Application No.: 09/754,723

Group Art Unit: 1614

Filed: January 4, 2001

Examiner: P. Duffy

Confirmation No: 3358

For: Use Of A Peptide



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. DeFronzo et al., "Efficacy of Metformin in Patients with Niddm."
N. England J. Med. Vol. 333, No. 9, pgs. 541-549

08/15/2002 NMOHAMM1 00000009 141447 09754723

01 FC:126 180.00 CH

2. Garber et al., "Efficacy of Metformin in Type II Diabetes: Results of a Double-Blind, Placebo-controlled, Dose-Response Trial The American Journal of Medicine Vol. 103, pgs. 491-497 (Dec. 1997)
3. Groop et al., "The Combination of Insulin and Sulphonylurea in the Treatment of Secondary Drug Failure in Patients with Type II Diabetes", Acta Endocrinologica Vol. 106. pgs. 97-101 (1984)
4. Prato et al., "Rationale for the Association of Sulfonylurea and Insulin" The American Journal of Medicine Vol. 90 (suppl 6A), pgs. 77S-82S (1991)
5. Gorus et al., "Interaction of Sulfonylureas With Pancreatic β -Cells" Diabetes Vol. 37., pgs. 1090-1095 (1988)
6. Gefel et al., "Glucagon-Like Peptide-I Analogs: Effects on Insulin Secretion and Adenosine 3', 5' -Monophosphate Formation", Endocrinology Vol. 126., pgs. 2164-2168 (1990)
7. Gutniak et al., "Glucagon-Like Insulinotropic Peptide 1 (7-36)-New Approach to Treating Diabetes" Diabetologica Vol. 33 Suppl. A73 (1990)
8. Nathan et al., "Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects" Diabetes Care Vol. 15, No. 2., pgs. 270-276 (1992)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

This information disclosure statement is being filed **after** the period set forth in 37 C.F.R. 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is

X the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: August 6, 2002

Richard W. Bork
 Richard W. Bork, Reg. No. 36,459
 Novo Nordisk of North America, Inc.
 405 Lexington Avenue, Suite 6400
 New York, NY 10174-6401
 (212) 867-0123



23650

PATENT TRADEMARK OFFICE